SEC 13F Intelligence

Foresite Capital Management IV, LLC / ACRS

Foresite Capital Management IV, LLC’s Aclaris Therapeutics Inc Position

Does Foresite Capital Management IV, LLC own Aclaris Therapeutics Inc (ACRS)? Not currently — the last reported position was 2.81M shares worth $19M in Q3 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$19M
Q3 2023
Shares
2.81M
% of Portfolio
+10.68%
Quarters Held
13
position exited

Position History ACRS

Reported value by quarter
Q3 ’20: $372,000Q3 ’20Q4 ’20: $6MQ1 ’21: $86MQ1 ’21Q2 ’21: $60MQ3 ’21: $61MQ3 ’21Q4 ’21: $49MQ1 ’22: $50MQ1 ’22Q2 ’22: $39MQ3 ’22: $44MQ3 ’22Q4 ’22: $44MQ1 ’23: $23MQ1 ’23Q2 ’23: $29MQ3 ’23: $19MQ3 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q3 20232.81M$19M+10.68%
Q2 20232.81M$29M+14.32%
Q1 20232.81M$23M+11.79%
Q4 20222.81M$44M+18.89%
Q3 20222.81M$44M+14.21%
Q2 20222.81M$39M+10.56%
Q1 20222.90M$50M+13.98%
Q4 20213.40M$49M+10.17%
Q3 20213.40M$61M+9.01%
Q2 20213.40M$60M+8.07%
Q1 20213.40M$86M+10.26%
Q4 2020951.4K$6M+0.67%
Q3 2020144.9K$372,000+0.08%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Foresite Capital Management IV, LLC’s full portfolio or all institutional holders of ACRS.